Hassig Christian 4

What Happened
Christian Hassig, Chief Scientific Officer of Boundless Bio, was granted a derivative award on January 23, 2026 for 230,000 shares. The filing reports an acquisition at $0.00 (derivative), and the award is described in the footnote as a stock option that vests in 48 substantially equal monthly installments beginning January 1, 2026 (1/48th vests on Feb 1, 2026 and monthly thereafter). This was an award/compensation grant, not an open-market purchase or sale.

Key Details

• Transaction date: January 23, 2026; Form 4 filed January 26, 2026. The filing does not show a late-filing notation.
• Security: Derivative award (stock option) for 230,000 shares; reported price $0.00 in the filing.
• Vesting: Commencement date Jan 1, 2026; vests in 48 substantially equal monthly installments (1/48th vests Feb 1, 2026, then monthly).
• Shares owned after transaction: Not specified in the information provided from the filing.
• No exercise or sale reported — this is a grant that will vest over time as compensation.

Context

• This is a compensation grant to an executive, which is routine and does not by itself signal buying or selling sentiment. Purchases are generally more indicative of bullish insider conviction; awards typically reflect company compensation programs.
• Because the award vests over four years, any potential value realization depends on future vesting and any exercise terms; there was no immediate cash transaction or sale reported.